Department of Sciences for Health Promotion and Mother-Child Care "G. D'Alessandro", University of Palermo, Via del Vespro 127, 90127, Palermo, Italy,
Curr Infect Dis Rep. 2014 Oct;16(10):428. doi: 10.1007/s11908-014-0428-7.
The prevalence of bacterial resistance to carbapenem antibiotics continues to increase because of bacteria producing metallo-β-lactamases (MBL), called carbapenemase-producing organisms (CPO). Enterobacteriaceae, which can be a common cause of intra-abdominal infections (IAIs), have become carbapenem-resistant Enterobacteriaceae (CRE). Updated international guidelines for the treatment of both IAIs and IAIs due to CRE have been published. Given the multifaceted nature of these infections, these recommendations have been jointly reviewed and endorsed by the Surgical Society and the Association of Medical Microbiology and Infectious Disease. The aims of this review are to summarize the general and new generation of multimodal procedure to manage IAIs due to CRE and review the data available on the combination of interventions to reduce CRE. Future research should focus on the development of novel and safe antimicrobial therapies and the quantification of the incremental effect of infection control programmes and new methods to rapidly detect pathogens before patients enter the surgical setting.
由于细菌产生金属β-内酰胺酶(MBL),即碳青霉烯酶产生菌(CPO),导致细菌对碳青霉烯类抗生素的耐药性持续增加。肠杆菌科可引起腹腔内感染(IAIs),已成为耐碳青霉烯肠杆菌科(CRE)。已经发布了针对IAIs 和 CRE 引起的 IAI 的治疗的最新国际指南。鉴于这些感染的多方面性质,这些建议已由外科学会和医学微生物学和传染病协会联合审查和认可。本综述的目的是总结针对 CRE 引起的 IAI 的一般和新一代多模式治疗方法,并回顾关于减少 CRE 的干预措施联合应用的数据。未来的研究应侧重于开发新型和安全的抗菌治疗方法,并量化感染控制计划和新方法的增量效果,以便在患者进入手术环境之前快速检测病原体。